Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HER3 (ERBB3) is a receptor tyrosine kinase and member of the EGFR/ERBB family. It functions primarily as a co-receptor due to its impaired kinase activity, forming heterodimers with other ERBB receptors like EGFR/HER1 or HER2/ERBB2 upon ligand binding (e.g., neuregulins). This heterodimerization leads to phosphorylation events and activation of downstream signaling cascades, including PI3K/AKT and MAPK/ERK, which are critical for cell growth, differentiation, and survival. Overexpression or dysregulation of HER3 is implicated in various cancers, making it an important therapeutic target.
Monoclonal antibodies targeting the receptor or its dimerization partners.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Receptor tyrosine-protein kinase ERBB3 (HER3).